Skip to main content

Table 2 Trial construct 1—symptomatic trial. Power to detect an expected 2.60-point difference in ADAS-cog change in the planned sample (n = 360)

From: Impact of potential modifications to Alzheimer’s disease clinical trials in response to disruption by COVID-19: a simulation study

Trial modification

Linear mixed effects model: categorical time

Linear mixed effects model: continuous time

Student’s t test

Original t test (for reference)

Scenario 1

.51

.35

.33

.80

Scenario 2

.89

.69

.72

.80

Scenario 3

.98

.85

.90

.80